Skip to main content
SpringerLink
Log in

Recent R&D Highlights

  • News & Views
  • Published:
Pharmaceutical & Diagnostic Innovation

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table 1
Table 2
Table 1

References

References

  1. AstraZeneca fails to get FDA Panel Support for Exanta (update2). Available from: http://quote.bloomberg.com/apps/news?pid+71000001&refer+uk&sid+abg5K19cXhJc 10 September 2004

  2. AstraZeneca. Company Update. Exanta disappoints: de-rating potential. Lehman Brothers Equity Research (2004).

    Google Scholar 

References

  1. Marketletter 2004; 31 (40): 11.

  2. COX-2 withdrawal — Therapeutic, R&D and pharmaceutical impact. LeadDiscovery (2004).

  3. Vioxx: Merck in Big Pain. Frost & Sullivan (2004).

  4. Major Pharmaceuticals. Merck’s Vioxx withdrawn — implications for other COX-2s. Lehman Brothers Equity Research (2004).

Download references

Rights and permissions

Reprints and permissions

About this article

Cite this article

Recent R&D Highlights. Pharmaceutical & Diagnostic Innovation 2, 13–16 (2004). https://doi.org/10.1007/BF03256944

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF03256944

Search

Navigation